3 most recent filings and news items mentioning MNPR. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/MNPR/news?limit=20"
Pull MNPR filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayMonopar Therapeutics initiated a rolling New Drug Application submission for ALXN1840 to treat Wilson disease. This regulatory advance represents a potential first novel mechanism of action in the US for decades.
View filing at SEC.gov →Monopar Therapeutics received Rare Pediatric Disease designation for ALXN1840 treating Wilson disease. This grants potential eligibility for a Pediatric Priority Review Voucher upon NDA approval.
View filing at SEC.gov →Monopar Therapeutics announced publication of Phase 2 study results demonstrating ALXN1840 (tiomolibdate choline) achieved statistically significant reductions in daily copper balance and increased fecal copper excretion in Wilson disease patients, with good tolerability. The pos
View filing at SEC.gov →